David has been involved with life sciences companies since 1985, including in the roles of research scientist, manager of drug discovery programs, advisor, and investor.
David most recently co-founded and serves as CEO of Aeglea BioTherapeutics, founded in December of 2013 to develop engineered human enzymes invented in the laboratory of George Georgiou, Ph.D. of The University of Texas at Austin. The convergence of discovery and technology has created a significant opportunity for Aeglea to impact both the treatment of inborn errors of metabolism and cancer.
Earlier, David was an investor with with Skyline Ventures for 10 years, leading financings in start-ups to mid-stage healthcare companies.
Before his fellowship, David was a consultant in biotechnology R&D, and before that spent 16 years as a scientist and research director at Genentech. As a senior scientist in the Molecular Biology and Cardiovascular Research Departments, he was responsible for initiating programs in drug discovery and new technology development, and was an early pioneer in the application of genomics to drug discovery. As Director of Cardiovascular Research, David was responsible for discovery efforts that resulted in eight drugs moving into clinical trials, including the successful cancer therapy Avastin. He also worked with the Business Development group on licensing activities, and was a member of the cross-functional therapeutic area team responsible for corporate strategic planning in the cardiovascular arena.
Education, Personal, and Fellowship
David holds BS and PhD degrees in biochemistry from the University of Toronto, Canada, and is a member of the Advisory Board of the Institute of Molecular Medicine at the University of California, San Diego.
He is an ardent SCUBA diver, underwater photographer, and (perhaps because he believes that past results do not necessarily predict future performance) roots for either the Red Sox or Yankees depending on who's winning.
David has authored over 60 peer-reviewed scientific publications and is an inventor on 7 issued or pending US patents.
David was a member of Kauffman Fellows Class 7, and served his fellowship under mentor John Freund at Skyline Ventures in Palo Alto, CA.